These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12924538)

  • 21. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
    Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.
    Bryson YJ; Mirochnick M; Stek A; Mofenson LM; Connor J; Capparelli E; Watts DH; Huang S; Hughes MD; Kaiser K; Purdue L; Asfaw Y; Keller M; Smith E;
    HIV Clin Trials; 2008; 9(2):115-25. PubMed ID: 18474496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults.
    van der Leur MR; Burger DM; la Porte CJ; Koopmans PP
    Ther Drug Monit; 2006 Oct; 28(5):650-3. PubMed ID: 17038880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.
    Burger DM; van Rossum AM; Hugen PW; Suur MH; Hartwig NG; Geelen SP; Scherpbier HJ; Hoetelmans RM; Vulto AG; de Groot R;
    Antimicrob Agents Chemother; 2001 Mar; 45(3):701-5. PubMed ID: 11181346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.
    van Rossum AM; Bergshoeff AS; Fraaij PL; Hugen PW; Hartwig NG; Geelen SP; Wolfs TF; Weemaes CM; De Groot R; Burger DM
    Pediatr Infect Dis J; 2002 Aug; 21(8):743-7. PubMed ID: 12192162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.
    Scherpbier HJ; Bekker V; van Leth F; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2006 Mar; 117(3):e528-36. PubMed ID: 16481448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.
    van Heeswijk RP; Khaliq Y; Gallicano KD; Bourbeau M; Seguin I; Phillips EJ; Cameron DW
    Clin Pharmacol Ther; 2004 Dec; 76(6):588-97. PubMed ID: 15592330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.
    Cruciani M; Gatti G; Vaccher E; Di Gennaro G; Cinelli R; Bassetti M; Tirelli U; Bassetti D
    J Antimicrob Chemother; 2005 Apr; 55(4):546-9. PubMed ID: 15728147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of nelfinavir in subjects with hepatic impairment.
    Damle B; Hewlett D; Hsyu PH; Becker M; Petersen A
    J Clin Pharmacol; 2006 Nov; 46(11):1241-9. PubMed ID: 17050789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.
    Hirt D; Urien S; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Treluyer JM
    Br J Clin Pharmacol; 2007 Nov; 64(5):634-44. PubMed ID: 17892516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients.
    Hennessy M; Clarke S; Spiers JP; Kelleher D; Mulcahy F; Hoggard P; Back D; Barry M
    Antivir Ther; 2004 Feb; 9(1):115-22. PubMed ID: 15040543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report.
    Jain AK; Venkataramanan R; Fridell JA; Gadomski M; Shaw LM; Ragni M; Korecka M; Fung J
    Liver Transpl; 2002 Sep; 8(9):838-40. PubMed ID: 12200787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics of nelfinavir in HIV-1-infected children.
    van Heeswijk RP; Scherpbier HJ; de Koning LA; Heymans HS; Lange JM; Beijnen JH; Hoetelmans RM
    Ther Drug Monit; 2002 Aug; 24(4):487-91. PubMed ID: 12142631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
    Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F
    AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats.
    Anderson BD; May MJ; Jordan S; Song L; Roberts MJ; Leggas M
    Drug Metab Dispos; 2006 Apr; 34(4):653-9. PubMed ID: 16434546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.
    Boffito M; Pozniak A; Kearney BP; Higgs C; Mathias A; Zhong L; Shah J
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4386-9. PubMed ID: 16189129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.
    Curras V; Hocht C; Mangano A; Niselman V; Mariño Hernández E; Cáceres Guido P; Mecikovsky D; Bellusci C; Bologna R; Sen L; Rubio MC; Bramuglia GF
    Pharmacology; 2009; 83(1):59-66. PubMed ID: 19052483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
    Stocker H; Herzmann C; Breske A; Kruse G; Berger M; Schulbin H; Hill A; Steinmüller J; Becker M; Arastéh K; Kurowski M
    J Antimicrob Chemother; 2007 Mar; 59(3):560-4. PubMed ID: 17255144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.